You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Concentra Group Holdings Parent, Inc. repurchased 800,000 shares from Robert A. Ortenzio and related entities for $41.80 per share, totaling $33,440,000; the transaction closed November 9, 2026.
Leadership transition effective November 1, 2026 appoints Matthew DiCanio CEO, William K. Newton Executive Chairman and Tanner Newton CFO. New employment agreements provide annual base salaries of $785,000, $550,000 and $425,000, respectively.
Concentra reported Q3 2026 revenue of $622.1 million, up 8.6%, and adjusted EBITDA of $140.2 million, up 17.9%, while raising 2026 revenue guidance to $2.36 billion to $2.38 billion and adjusted EBITDA guidance to $505 million to $510 million.
Concentra Group Holdings Parent reported third-quarter revenue growth of 8.6% to $622.1 million, driven by 4.9% growth in patient visits and a 3.3% increase in revenue per visit to $152.14.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Concentra delivered strong Q3 growth, expanded margins, broadened its footprint and raised 2026 guidance, while also authorizing a $250 million share repurchase program. The main offsets were lower operating cash flow and free cash flow, a higher adjusted G&A ratio, moderating organic growth and uncertainty around 2027 workers' compensation rates.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Earnings per Share non-GAAP | $0.92 | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA non-GAAP | $261.62M | Six Months Ended June 30, 2026 | — |
| Adjusted Net Income Attributable to the Company non-GAAP | $118.14M | Six Months Ended June 30, 2026 | — |
| Consumer health patient visits | 108,131 | Six Months Ended June 30, 2026 | — |
| Consumer health revenue per visit | $136.16 | Six Months Ended June 30, 2026 | — |
| Consumer health VPD volume | 851 | Six Months Ended June 30, 2026 | — |
| Employer services patient visits | 3,689,568 | Six Months Ended June 30, 2026 | — |
| Employer services VPD volume | 29,052 | Six Months Ended June 30, 2026 | — |
| Free Cash Flow non-GAAP | $130.95M | Six Months Ended June 30, 2026 | — |
| Free Cash Flow Conversion non-GAAP | 131% | TTM Jun. 30, 2026 | — |
| Number of occupational health centers—end of period | 633 | Six Months Ended June 30, 2026 | — |
| Number of onsite health clinics—end of period | 415 | Six Months Ended June 30, 2026 | — |
| Return on Invested Capital non-GAAP | 14.6% | TTM Jun. 30, 2026 | — |
| Revenue per visit | $152.08 | Six Months Ended June 30, 2026 | — |
| Revenue per visit for employer services visits | $96.36 | Six Months Ended June 30, 2026 | — |
| Segment Adjusted EBITDA non-GAAP | $140.93M | Three Months Ended June 30, 2026 filing | — |
| Total patient visits | 7,030,025 | Six Months Ended June 30, 2026 | — |
| VPD volume | 55,355 | Six Months Ended June 30, 2026 | — |
| Workers' compensation patient visits | 3,232,326 | Six Months Ended June 30, 2026 | — |
| Workers' compensation revenue per visit | $216.22 | Six Months Ended June 30, 2026 | — |
| Workers' compensation VPD volume | 25,451 | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CON
this stock
Concentra Group Holdings Parent, Inc.
|
$5.38B | +116.2% | +13.9% | 25.2 | 1.8% |
|
HCA
HCA Healthcare, Inc.
|
$104.25B | +6.9% | +7.1% | 16.6 | 2.3% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$33.34B | +3.3% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$22.76B | +43.9% | +0.9% | 8.3 | 2.2% |
|
EHC
Encompass Health Corp
|
$13.83B | +32.8% | +10.5% | 22.0 | 3.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Concentra Group Holdings Parent, Inc. repurchased 800,000 shares from Robert A. Ortenzio and related entities for $41.80 per share, totaling $33,440,000; the transaction closed November 9, 2026.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CON | +0.8% | +10.4% | +66.7% | +5.4% | +116.2% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -1.8% | +11.6% | +66.2% | +5.6% | +105.6% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
